Recruiting NCT07317206
Ayahuasca, Esketamine and PTSD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Ayahuasca, Esketamine.
- Who it may be relevant to
- Registry conditions: Posttraumatic Stress Disorder (PTSD). Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Brazil
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study
Overview
Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.
Interventions
- Drug Ayahuasca
oral ayahuasca - Drug Esketamine
oral esketamine
Primary outcome measures
- Posttraumatic Stress Disorder Checklist for DSM-5 [Time frame: From enrollment to the end of treatment at 3 weeks]
Eligibility criteria
Inclusion criteria
- posttraumatic stress disorder
Exclusion criteria
- psychiatric and other medical comorbidities
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Brazil · 1 center
- Hospital das Clínicas da FMRP-USP — Ribeirão Preto
Identifiers
NCT: NCT07317206 · 55068322.2.0000.5440